What is HC Wainwright's Forecast for Immunovant Q2 Earnings?

Key Points

• HC Wainwright lowered their Q2 2026 earnings estimate for Immunovant to ($0.79) per share, down from a previous forecast of ($0.76).
• The consensus rating for Immunovant's stock remains a "Moderate Buy" with a price target of $35.20 from various analysts.
• Immunovant's stock recently traded at $15.32, with a market capitalization of $2.67 billion.

Immunovant, Inc. (NASDAQ:IMVT - Free Report) - Equities research analysts at HC Wainwright dropped their Q2 2026 earnings estimates for Immunovant in a research report issued on Tuesday, August 12th. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings per share of ($0.79) for the quarter, down from their previous estimate of ($0.76). The consensus estimate for Immunovant's current full-year earnings is ($2.69) per share. HC Wainwright also issued estimates for Immunovant's Q3 2026 earnings at ($0.83) EPS, Q4 2026 earnings at ($0.88) EPS, FY2026 earnings at ($3.24) EPS, Q1 2027 earnings at ($0.91) EPS, Q2 2027 earnings at ($0.95) EPS, Q3 2027 earnings at ($0.96) EPS, Q4 2027 earnings at ($0.92) EPS, FY2027 earnings at ($3.73) EPS, FY2028 earnings at ($3.60) EPS, FY2029 earnings at ($0.55) EPS and FY2030 earnings at $2.69 EPS.

Several other analysts have also recently weighed in on the stock. Citigroup reaffirmed a "buy" rating on shares of Immunovant in a report on Monday, August 11th. Bank of America reduced their target price on shares of Immunovant from $33.00 to $30.00 and set a "buy" rating on the stock in a report on Tuesday, August 12th. The Goldman Sachs Group raised shares of Immunovant to a "hold" rating and set a $18.00 target price on the stock in a report on Thursday, July 10th. UBS Group raised their target price on shares of Immunovant from $17.00 to $18.00 and gave the company a "neutral" rating in a report on Monday, July 28th. Finally, JPMorgan Chase & Co. reduced their target price on shares of Immunovant from $40.00 to $37.00 and set an "overweight" rating on the stock in a report on Tuesday, August 12th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $35.20.

Immunovant Price Performance

Shares of NASDAQ IMVT traded down $0.34 during midday trading on Thursday, hitting $14.92. The company's stock had a trading volume of 369,445 shares, compared to its average volume of 1,460,126. The business's fifty day simple moving average is $16.48 and its two-hundred day simple moving average is $16.82. Immunovant has a 1 year low of $12.72 and a 1 year high of $34.47. The firm has a market capitalization of $2.60 billion, a price-to-earnings ratio of -5.23 and a beta of 0.66.

Immunovant (NASDAQ:IMVT - Get Free Report) last announced its earnings results on Monday, August 11th. The company reported ($0.60) earnings per share for the quarter, topping the consensus estimate of ($0.69) by $0.09. During the same quarter in the previous year, the business posted ($0.60) EPS.

Institutional Investors Weigh In On Immunovant

Several institutional investors and hedge funds have recently made changes to their positions in IMVT. Alliancebernstein L.P. increased its stake in shares of Immunovant by 5.9% during the 4th quarter. Alliancebernstein L.P. now owns 74,850 shares of the company's stock valued at $1,854,000 after acquiring an additional 4,200 shares during the last quarter. Geode Capital Management LLC grew its position in Immunovant by 0.3% in the fourth quarter. Geode Capital Management LLC now owns 1,515,020 shares of the company's stock valued at $37,536,000 after acquiring an additional 4,094 shares in the last quarter. Wells Fargo & Company MN grew its position in Immunovant by 50.0% in the fourth quarter. Wells Fargo & Company MN now owns 28,063 shares of the company's stock valued at $695,000 after acquiring an additional 9,349 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in Immunovant in the fourth quarter valued at approximately $505,000. Finally, XTX Topco Ltd acquired a new stake in Immunovant in the fourth quarter valued at approximately $563,000. 47.08% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Immunovant

In related news, CTO Jay S. Stout sold 2,805 shares of the business's stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $18.15, for a total value of $50,910.75. Following the sale, the chief technology officer directly owned 204,919 shares in the company, valued at $3,719,279.85. The trade was a 1.35% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Michael Geffner sold 2,385 shares of the business's stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $18.15, for a total transaction of $43,287.75. Following the completion of the sale, the insider owned 221,825 shares in the company, valued at $4,026,123.75. This represents a 1.06% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 7,869 shares of company stock worth $140,384 over the last 90 days. Insiders own 1.80% of the company's stock.

Immunovant Company Profile

Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.